Analyst Comment
New partnership for Aiforia
Summary
- Aiforia announced a partnership with Proscia to integrate their AI applications with Proscia's Concentriq platform, enhancing availability to Proscia's customers.
- The integration allows Aiforia's software to be used directly on platforms familiar to pathologists, reducing adoption barriers and supporting digital workflow transitions.
- Aiforia's position in the European clinical digital pathology market is strong, but revenue growth has been slow; partnerships like Proscia are expected to drive scalable growth and profitability.
- The partnership is anticipated to contribute to Aiforia's projected revenue growth to 5.1 MEUR in 2026, representing a 45% increase.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 3/11/2026 at 7:23 am EET.
Aiforia announced on Tuesday that it has entered into a partnership with Proscia, a pathology software company. Through this collaboration, the companies' solutions will be integrated, improving the availability of Aiforia's AI applications to Proscia's customer base. The news further supports the company's growth prospects, which are already significantly embedded in our forecast.
Integration facilitates adoption of Aiforia's applications
The partnership centers on the integration of Aiforia's AI-powered diagnostic applications with Proscia's Concentriq platform. Proscia is one of the key players in the field, and according to the press release, its solutions are used by 16 of the world's 20 largest pharmaceutical companies. The integration enables the utilization of data produced by Aiforia's software directly on the platform that pathologists already use. This lowers the barrier to adopting Aiforia's technology, as laboratories do not need to change their established processes. Additionally, the companies, together with Siemens Healthineers, offer a comprehensive solution for transitioning to fully digital workflows, which can strengthen Aiforia's position as part of a broader ecosystem.
Partnerships support our growth forecasts
Aiforia has already achieved a strong position in the developing clinical digital pathology market in Europe, but new customer acquisitions have been slow to translate into revenue. However, the company's recent H2'25 report showed signs of growth in the clinical segment. In our view, ecosystem partnerships like Proscia are an important addition on the path to achieving scalable growth and ultimately a turnaround in profitability. We expect Aiforia's revenue to grow to 5.1 MEUR in 2026 (+45%), and the newly announced partnership is one concrete driver behind this growth.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures08.03
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 3.5 | 5.1 | 7.9 |
| growth-% | 24.0 % | 45.0 % | 55.0 % |
| EBIT (adj.) | -11.2 | -9.2 | -8.3 |
| EBIT-% (adj.) | -316.3 % | -178.7 % | -104.7 % |
| EPS (adj.) | -0.38 | -0.25 | -0.19 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
